Key Segmentation:
By Component
-
Software
-
Services
-
Hardware
By Technology
-
Deep Learning
-
Machine Learning
-
Natural Language Processing
-
Others
By Application
-
Oncology
-
Neurology
-
Cardiology
-
Respiratory
-
Others
By End User
-
Healthcare Providers
-
Pharma & Biotech
-
Academic & Research Institutes
-
Others
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Tempus AI, Illumina, SOPHiA GENETICS, Caris Life Sciences, Owkin, PathAI, Lunit, Freenome, GeneDx, QIAGEN, DNAnexus, Roche, Ibex Medical Analytics, NVIDIA and Google DeepMind.
Key opportunities include multi-cancer detection and liquid biopsy, digital pathology, generative AI assistants for records and trial matching, and growth in Asia and the Gulf.
Rapid growth in genomic and clinical data, falling sequencing cost and rising clinical validation are the main growth factors, supported by government programs.
By Component, the Software segment dominated the market in 2025 with an estimated 41.50% share, supported by its role as the core intelligence layer for diagnosis and treatment decisions.
North America dominated the market with a share of 41.65% in 2025, driven by leading cancer centers, genomic testing firms and strong funding.